Endocrine Abstracts

Gonadotroph tumours (GoTs) are frequent intracranial neoplasms that represent 30% of all pituitary tumours (PiTs). While GoTs are responsible of an important morbidity, their tumorigenesis is not yet understood, and their treatment is limited to surgical resection and radiotherapy. The absence of identified driver-genes combined with their heterogeneity and silent behaviour (i.e. lack of hormone hypersecretion) limit the development of medical treatment. The current lack of re...

Introduction: Pituitary Neuroendocrine tumours (PitNETs) present heterogenic characteristics based on their hormonal expression and secretion. While most PitNETs have a slow progression rate, a subset of them exhibit an aggressive behaviour with recurrence properties despite current surgery, radio- and chemotherapy. To explore new clinical strategies based on immunotherapy we initiated a systemic cartography of the pituitary tumour immune microenvironment (PiTME).<p class=...

Background: Tumour microenvironment (TME) can comprise >50% of the tumour mass and includes non-tumour cells like immune cells and fibroblasts, as well as extracellular matrix, signaling molecules, and blood and lymph vessels. In recent years, TME has begun to be considered both a prognostic tool and a therapeutic target. While the existence of TME is well accepted and described in numerous cancers, little is known about the TME of pituitary neuroendocrine tumours (PitNETs...